Human cell chimerism in the spleen of newborn-engrafted mice at 12 weeks of age
| Human cell subset . | NSG-Tg(hu-mSCF), 0 cGy, (N = 10) . | NSG, 0 cGy, (N = 8) . | NSG-Tg(hu-mSCF), 100 cGy, (N = 7) . | NSG, 100 cGy, (N = 10) . | ||||
|---|---|---|---|---|---|---|---|---|
| % . | No, × 106 . | % . | No, × 106 . | % . | No, × 106 . | % . | No, × 106 . | |
| Total human leukocytes: CD45+ | 70.0 ± 9.2 | 18.5 ± 12.4* | 61.2 ± 19 | 7.6 ± 6.7 | 62.8 ± 17 | 7.5 ± 7.0 | 66.9 ± 11 | 10.3 ± 12.5 |
| B-cell lineage, % of CD45 | ||||||||
| CD20+ | 34.4 ± 19 | 45.6 ± 16 | 31.1 ± 21 | 42.5 ± 13 | ||||
| CD10+/20+ | 15.0 ± 8.9 | 23.7 ± 12 | 12.1 ± 13 | 16.6 ± 7.9 | ||||
| T-cell lineage, % of CD45 | ||||||||
| CD3+/CD4+ | 18.0 ± 14.4 | 10.6 ± 8.0 | 16.8 ± 8.1 | 12.8 ± 9.4 | ||||
| RA:RO ratio | 1.61 ± 3.5 | 1.59 ± 0.94 | 0.17 ± 0.25 | 0.41 ± 0.38 | ||||
| CD3+/CD8+ | 14.3 ± 16 | 7.17 ± 4.4 | 11.2 ± 6.5 | 7.47 ± 3.32 | ||||
| RA:RO ratio | 1.52 ± 2.0 | 4.51 ± 1.8 | 0.88 ± 0.8 | 3.36 ± 3.56 | ||||
| Myeloid/granulocytic, % of CD45 | ||||||||
| CD33+ | 8.33 ± 13 | 10.6 ± 0.41 | 12.3 ± 22 | 1.45 ± 1.4 | ||||
| CD33+/64+ | 0.17 ± 0.54 | 0.0 ± 0.0 | 0.33 ± 0.8 | 0.00 ± 0.0 | ||||
| CD14+ | 1.11 ± 1.1 | 0.21 ± 0.15 | 1.10 ± 0.90 | 1.06 ± 0.82 | ||||
| Dendritic cell subsets, % of CD45 | ||||||||
| CD11c+ | 0.08 ± 0.08 | 2.02 ± 2.58 | 0.13 ± 0.06 | 0.18 ± 0.20 | ||||
| CD123+ | 0.20 ± 0.20 | 0.25 ± 0.19 | 0.28 ± 0.17 | 0.26 ± 0.27 | ||||
| Human cell subset . | NSG-Tg(hu-mSCF), 0 cGy, (N = 10) . | NSG, 0 cGy, (N = 8) . | NSG-Tg(hu-mSCF), 100 cGy, (N = 7) . | NSG, 100 cGy, (N = 10) . | ||||
|---|---|---|---|---|---|---|---|---|
| % . | No, × 106 . | % . | No, × 106 . | % . | No, × 106 . | % . | No, × 106 . | |
| Total human leukocytes: CD45+ | 70.0 ± 9.2 | 18.5 ± 12.4* | 61.2 ± 19 | 7.6 ± 6.7 | 62.8 ± 17 | 7.5 ± 7.0 | 66.9 ± 11 | 10.3 ± 12.5 |
| B-cell lineage, % of CD45 | ||||||||
| CD20+ | 34.4 ± 19 | 45.6 ± 16 | 31.1 ± 21 | 42.5 ± 13 | ||||
| CD10+/20+ | 15.0 ± 8.9 | 23.7 ± 12 | 12.1 ± 13 | 16.6 ± 7.9 | ||||
| T-cell lineage, % of CD45 | ||||||||
| CD3+/CD4+ | 18.0 ± 14.4 | 10.6 ± 8.0 | 16.8 ± 8.1 | 12.8 ± 9.4 | ||||
| RA:RO ratio | 1.61 ± 3.5 | 1.59 ± 0.94 | 0.17 ± 0.25 | 0.41 ± 0.38 | ||||
| CD3+/CD8+ | 14.3 ± 16 | 7.17 ± 4.4 | 11.2 ± 6.5 | 7.47 ± 3.32 | ||||
| RA:RO ratio | 1.52 ± 2.0 | 4.51 ± 1.8 | 0.88 ± 0.8 | 3.36 ± 3.56 | ||||
| Myeloid/granulocytic, % of CD45 | ||||||||
| CD33+ | 8.33 ± 13 | 10.6 ± 0.41 | 12.3 ± 22 | 1.45 ± 1.4 | ||||
| CD33+/64+ | 0.17 ± 0.54 | 0.0 ± 0.0 | 0.33 ± 0.8 | 0.00 ± 0.0 | ||||
| CD14+ | 1.11 ± 1.1 | 0.21 ± 0.15 | 1.10 ± 0.90 | 1.06 ± 0.82 | ||||
| Dendritic cell subsets, % of CD45 | ||||||||
| CD11c+ | 0.08 ± 0.08 | 2.02 ± 2.58 | 0.13 ± 0.06 | 0.18 ± 0.20 | ||||
| CD123+ | 0.20 ± 0.20 | 0.25 ± 0.19 | 0.28 ± 0.17 | 0.26 ± 0.27 | ||||
Nonirradiated NSG and NSG-Tg(hu-mSCF), and 100-cGy irradiated NSG and NSG-Tg(hu-mSCF) newborn mice were engrafted with human HSCs as described in “Engraftment of mice with human HSCs.” Mice were analyzed by flow cytometry for the percentage and number of human CD45+ and the percentage of human CD45+ cells that were positive for specific lineage markers in the spleen at 16-20 weeks of age. Data are mean ± SD.
Nonirradiated NSG-Tg(hu-mSCF) vs nonirradiated NSG (P < .05).